Sellas Life Sciences Group, Inc. SLS
Sellas Life Sciences Group, Inc. (Nasdaq: SLS) is a hematology drug developer. Its lead program, Galinpepimut-S (GPS), is in Phase 3 for Acute myeloid leukemia (AML) maintenance, second complete remission (CR2). Its next catalyst on record is SLS009: Topline data for SLS009 Phase 2 trial in newly diagnosed first-line AML expected in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SLS009 — Topline data for SLS009 Phase 2 trial in newly diagnosed first-line AML expected in Q4 2026. (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Galinpepimut-S (GPS) | Acute myeloid leukemia (AML) maintenance, CR2 | protein/peptide | Phase 3 |
| SLS009 (tambiciclib) | Newly diagnosed, first-line AML eligible for aza/ven therapy | small molecule | Phase 2 |
| SLS009 (tambiciclib) | Relapsed/refractory AML | small molecule | Phase 2 |
Recent results and decisions
- Aug 11, 2026n/a SELLAS obtained promising preclinical results for SLS009 in PDAC and intends to support clinical development at a top-tier academic institution.
SLS009 has demonstrated the ability to act as a single agent in PDAC cells largely resistant to leading RAS inhibitors and synergize with the RAS inhibition mechanism of action.
Filing - Mar 19, 2026started First patient dosed in 80-patient Phase 2 trial of SLS009 with AZA/VEN in newly diagnosed/early-refractory AML.
After receiving constructive feedback from the FDA, SELLAS dosed the first patient in an 80-patient trial in newly diagnosed AML patients as well as those who become refractory early to AZA/VEN treatment which we established through our extensive transcriptomics, genomics, and proteomics models.
Filing - Mar 19, 2026positive Phase 2 SLS009 + AZA/VEN in r/r AML-MR (ASH Dec 2025): ORR 46%, CR/CRi 29% among 35 evaluable patients; no DLTs.
among the 35 evaluable patients, the overall response rate (CR/Cri/MLFS) was 46%, including 29% achieving CR/CRi.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
- BeOne Medicines Ltd. ONC
- Incyte Corp INCY
- Grifols SA GRFS
- Cogent Biosciences, Inc. COGT
- Disc Medicine, Inc. IRON
- Beam Therapeutics Inc. BEAM
- Agios Pharmaceuticals, Inc. AGIO
- Cerus Corporation CERS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.